Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
2000 1
2002 1
2005 1
2006 1
2007 3
2008 3
2009 9
2010 3
2011 8
2012 10
2013 7
2014 9
2015 13
2016 19
2017 14
2018 17
2019 13
2020 6
2021 3
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29931425

133 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP, Fasching PA, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Janni W, Rack B, Scholz C; SUCCESS Study Group. Bauer ECA, et al. Breast Cancer Res Treat. 2018 Oct;171(3):571-580. doi: 10.1007/s10549-018-4856-1. Epub 2018 Jun 21. Breast Cancer Res Treat. 2018. PMID: 29931425
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W; SUCCESS Study Group. Jueckstock J, et al. BMC Cancer. 2016 Jul 7;16:401. doi: 10.1186/s12885-016-2454-3. BMC Cancer. 2016. PMID: 27387743 Free PMC article. Clinical Trial.
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm TN, Pantel K, Fasching PA, Schneeweiss A, Janni W, Rack BK; SUCCESS Study Group. Schramm A, et al. Clin Breast Cancer. 2017 Jul;17(4):279-285. doi: 10.1016/j.clbc.2016.11.008. Epub 2017 Jan 10. Clin Breast Cancer. 2017. PMID: 28190761 Clinical Trial.
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group. Trapp E, et al. J Natl Cancer Inst. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152. J Natl Cancer Inst. 2019. PMID: 30312434 Clinical Trial.
Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K. Iwata H, et al. Breast Cancer Res Treat. 2017 Apr;162(3):501-510. doi: 10.1007/s10549-017-4138-3. Epub 2017 Feb 8. Breast Cancer Res Treat. 2017. PMID: 28181129
133 results